A Budaj, JW Eikelboom, SR Mehta, R Afzal, S … - European Heart Journal, 2009 - Eur Soc Cardiology Methods and results: Nine hundred and ninety (4.9%) patients developed major
bleeding and 423 (2.1%) developed minor bleeding. Fondaparinux compared with
enoxaparin reduced fatal bleeding [0.07 vs. 0.22%, relative risk (RR) 0.30, ... Cited by 13 - Related articles - All 3 versions
- ►critcaremed.com CD Joyner, RJG Peters, R Afzal, S … - American Heart Journal, 2009 - Elsevier The impact of fondaparinux versus enoxaparin on the primary outcome of death,
myocardial infarction, and refractory ischemia at 180 days was similar in the
low-, intermediate-, and high-risk groups: 7.0% versus 7.7% (hazard ratio ... Cited by 5 - Related articles - All 7 versions
- ►critcaremed.org M Sobieraj-Teague, AS Gallus, JW Eikelboom - Current opinion in cardiology, 2008 - journals.lww.com Recent findings: Bleeding is a common complication of antithrombotic treatment
in acute coronary syndrome, and major bleeding occurs in around 5% of patients.
Important risk factors for major bleeding include increasing age, female ... Cited by 3 - Related articles - All 7 versions
- ►uwmcacc.org [PDF] EA Nutescu, SA Spinler, A Wittkowsky, WE … - The Annals of Pharmacotherapy, 2009 - Harvey Whitney Books Standardized prophylaxis or treatment doses of low-molecular-weight hep- arins
(LMWHs) can be used in most pa- tients without dose adjustment. Howev- er, there
are concerns about whether dose adjustments are needed to optimize ... Cited by 2 - Related articles - All 5 versions
SA Spinler, KW Mahaffey, D Gallup, GN … - International Journal of Cardiology, 2009 - Elsevier Of 9838 patients with a CrCl value, 70.6% (N = 6950) had CrCl ≥ 60 mL/min,
27.8% (N = 2732) had CrCl 30–59 mL/min, and 1.6% (N = 156) had CrCl < 30
mL/min. No randomized treatment by CrCl interaction test was found to be ... Cited by 1 - Related articles - All 2 versions
FM Cardiology - medscape.com This activity is intended for cardiologists. It may also be of interest to
emergency department physicians, nurses, and other healthcare professionals who
are involved in the treatment and diagnosis of patients with ST-segment ... Related articles
CD Joyner, RJG Peters, R Afzal, S … - American Heart Journal, 2009 - pt.wkhealth.com Background: The OASIS-5 (Organization to Assess Strategies in Ischemic
Syndromes-5) trial demonstrated that fondaparinux was noninferior to enoxaparin
while reducing the risk of bleeding by 50%. The objectives of our study ...
K Meijer, S Schulman - Seminars in Thrombosis and Hemostasis, 2008 - pt.wkhealth.com The risk of bleeding associated with antithrombotic and fibrinolytic therapy
depends on factors that are specific for the drugs and the patients. In this
narrative review, we describe the most important risk factors for bleeding ...
K Meijer, S Schulman - Seminars in Thrombosis & Hemostasis, 2008 - thieme-connect.com The risk of bleeding associated with antithrombotic and fibrinolytic therapy
depends on factors that are specific for the drugs and the patients. In this
narrative review, we describe the most important risk factors for bleeding ... Related articles - All 4 versions
